Devonian Health Group Inc. (CVE:GSD – Get Free Report) traded up 4.2% during mid-day trading on Thursday . The company traded as high as C$0.25 and last traded at C$0.25. 44,980 shares traded hands during trading, an increase of 124% from the average session volume of 20,061 shares. The stock had previously closed at C$0.24.
Devonian Health Group Stock Performance
The business’s fifty day moving average price is C$0.20 and its 200-day moving average price is C$0.18. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The stock has a market cap of C$37.06 million, a PE ratio of -12.50 and a beta of 1.28.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- Investing in Travel Stocks Benefits
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Canadian Penny Stocks: Can They Make You Rich?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
